AbCellera Results Presentation Deck

2020 BUSINESS UPDATE. COVID-19 PROGRAM COMBAT VARIANTS WITH BAMLANIVIMAB COMBINATIONS Bamlanivimab is being evaluated together with other antibodies in patients recently diagnosed with mild to moderate COVID-19 to address emerging variants. bamlanivimab + etesevimab Reduces hospitalization & death by 87% in patients recently diagnosed with mild to moderate COVID-19. US UK 99% effective against circulating strains in US Effective against UK strain bamlanivimab + VIR-7831 Currently being evaluated in the BLAZE-4 study for patients recently diagnosed with mild to moderate COVID-19. SA Predicted to be effective against South African strain Ab Cellera COPYRIGHT ABCELLERA 11

View entire presentation